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A major requirement for cancer immunotherapy is the
development of biomarkers for prognosis, as well as for
monitoring the success of the undergoing therapy.
In an attempt to evaluate the immune response of renal
cell carcinoma (RCC) patients, tumor lesions and / or
blood samples from 12 patients with clear cell RCC under-
went deep T cell receptor (TCR) sequencing using the
immunoSEQ assay (Adaptive Biotechnologies). Despite
the low number of samples, different TCR distribution
patterns could be detected. Most of the RCC patients pre-
sented “patient-specific” TCR sequences corresponding to
>1% of their TCR repertoire that were shared between
peripheral blood and tumor tissue. Frequently, an enrich-
ment of these TCR sequences was found in the RCC
lesion when compared to the peripheral blood of the
patient. In addition, TCR patterns shared by different RCC
patients were identified, which were only present in their
tumor lesions, but not in peripheral blood. In particular, a
group of 6 RCC patients shared between 4 and 6 TCR
sequences, while other 3 RCC patients shared between
4 and 8 different TCRs. The relative frequencies of those
shared TCRs among the different donors were very differ-
ent, varying from below 1% to a maximum of 37% of the
total TCR repertoire.
Analysis of additional samples and correlation of the
TCR sequencing data with clinical parameters could lead
to a correlation of particular TCRs with an RCC patient’s
prognosis or T cell clone expansion under therapy and
thus provide important information for patient treatment.
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